All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, August 14, 2022
Home » Blogs » BioWorld Perspectives » First-Half Biotech Fundraising: What You Need to Know

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

First-Half Biotech Fundraising: What You Need to Know

July 11, 2011
By Trista Morrison
No Comments

We just finished running the numbers for biotech fundraising in the first half of 2011, and . . . drum roll please . . . the numbers are good! Well, they’re good if you’re a publicly traded, pre-commercial biotech, anyway.

Overall, biotech companies raised a total of $13.3 billion in the first half of 2011, up a whopping 64 percent over the $8.1 billion raised in the first half of 2010, according to data from BioWorld Insight and BioWorld Snapshots.

That breaks down into three categories: $2.1 billion raised by private biotechs, $4.6 billion raised in initial and follow-on public offerings, and $6.6 billion from alternative financings of public companies (i.e. registered directs, PIPEs, loans, ATMs, etc.) The latter two categories about doubled over the first half of 2010, while the private company money fell slightly.

You can read details on the public company data in Monday’s BioWorld Today and the full report in Monday’s BioWorld Insight. But here are a few key takeaways:

  • The big money in follow-ons is going to pre-commercial biotechs. You’ve got Nektar Therapeutics Inc. raising $234.5 million, Exelixis Inc. raising $189.75 million and Seattle Genetics Inc. raising $178.25 million, to name a few. As the biotech industry matures and more companies get a stock boost off late-stage clinical milestones, expect to see more padding of the coffers to fund product launches.
  • PIPEs and registered directs are still important, but the new fundraising mechanism of choice is the wall-cross follow-on offering, in which companies market a deal privately for a few days and then sell the rest publicly.
  • The IPO window is about as open as Chik-fil-A on Sundays. But clearly not everyone has given up hope ? Clovis Oncology Inc. just filed, and there are rumors that some other big filings are in the works. [UPDATE: Not just a rumor anymore. Merrimack Pharmaceuticals Inc. filed for $172.5M IPO]
  • Private biotech funding has that “cautious optimism” feel, and VCs report increasing interest in innovation. There’s a lot of business model experimentation going on, especially around product development companies. More on that coming soon in BioWorld Insight!

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 12, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 12, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing